technetium tc-99m nofetumomab merpentan

Technetium Tc-99m nofetumomab merpentan is a **diagnostic radioimmunoscintigraphic agent** formerly marketed as Verluma. It comprises the Fab fragment of the murine IgG2b monoclonal antibody NR-LU-10, termed nofetumomab, conjugated through the chelator merpentan to technetium-99m. The antibody fragment binds a carcinoma-associated approximately 40 kDa cell-surface glycoprotein expressed across many epithelial carcinomas; the Tc-99m label enables gamma-camera imaging of tumor sites. It was approved in the United States for detection of extensive-stage disease in patients with biopsy-confirmed, previously untreated small cell lung cancer, rather than for cancer treatment. The biologic license is listed as discontinued. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1996/nofedrk082096L.htm))

Brand names

Verluma

Other names

technetium (99mTc) nofetumomab merpentanTc-99m nofetumomab merpentanTc99m nofetumomab merpentanTc 99m nofetumomab merpentanTc-99m NR-LU-10Tc99m NR-LU-10Tc 99m NR-LU-10